Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
May 2 ABBV Top 25 Stocks in the S&P 500 by Index Weight Right Now
May 2 UTHR United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
May 2 UTHR United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript
May 2 VRTX 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 UTHR United Therapeutics Corp (UTHR) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...
May 2 ABBV The top pharmaceutical companies by R&D expenditure
May 2 UTHR Q1 2024 United Therapeutics Corp Earnings Call
May 1 UTHR Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
May 1 ABBV BeiGene, AbbVie patent spat to get trial from USPTO appeals board
May 1 UTHR United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript
May 1 ABBV CVS stock plunges after earnings numbers one analyst 'did not even believe'
May 1 VRTX Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
May 1 IONS 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
May 1 UTHR Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics
May 1 VRTX Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
May 1 INO INOVIO Reports Inducement Grants Under Inducement Plan
May 1 BNTC Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 1 UTHR United Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
May 1 UTHR United Therapeutics GAAP EPS of $6.17 beats by $0.51, revenue of $677.7M beats by $53.51M
May 1 UTHR United Therapeutics Corporation Reports First Quarter 2024 Financial Results
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags